Pulmonary surfactant (medication)

Medication

Pharmaceutical compound

Pulmonary surfactant

Carton of beractant (Survanta), surrounded by devices for its application.

Clinical data
Pronunciation| Curosurf, Survanta, others
Other names| Beractant, Poractant alfa, others
AHFS/Drugs.com| Monograph
License data|

* US DailyMed: Poractant_alfa

ATC code|

* R07AA (WHO)

Identifiers
CAS Number|

* 129069-19-8 Y

ChemSpider|

* none

UNII|

* KE3U2023NP

Pulmonary surfactant is used as a medication to treat and prevent respiratory distress syndrome in newborn babies.[1]

Prevention is generally done in babies born at a gestational age of less than 32 weeks.[1] It is given by the endotracheal tube.[1] Onset of effects is rapid.[2] A number of doses may be needed.[2]

Side effects may include slow heart rate and low oxygen levels.[1] Its use is also linked with intracranial bleeding.[1] Pulmonary surfactant may be isolated from the lungs of cows or pigs or made artificially.[1][3][4]

Pulmonary surfactant was discovered in the 1950s and a manufactured version was approved for medical use in the United States in 1990.[3] It is on the World Health Organization's List of Essential Medicines.[5]

## Medical uses

[edit]

Pulmonary surfactant is used to treat and prevent respiratory distress syndrome in newborn babies.[1] Prevention is generally done in babies born less than 32 weeks gestational age.[1] Tentative evidence supports use in drowning.[6]

Surfactant administration can also be effective in meconium aspiration syndrome where it has been shown to help lower length of stay.[7][8]

## Types

[edit]

See also: Pulmonary surfactant § composition

There are a number of types of pulmonary surfactants available. Like their natural counterparts, pulmonary surfactant preparations consist of phospholipids (mainly DPPC) combined with spreading agents such as SP-B and SP-C.[9] Ex-situ measurements of surface tension and interfacial rheology can help to understand the functionality of pulmonary surfactants.[10]

Synthetic pulmonary surfactants:

* Colfosceril palmitate (Exosurf) – a mixture of DPPC with hexadecanol and tyloxapol added as spreading agents
* Pumactant (Artificial Lung Expanding Compound or ALEC) – a mixture of DPPC and PG
* Lucinactant (KL4, trade name Surfaxin) – composed of DPPC, palmitoyl-oleoyl phosphatidylglycerol, and palmitic acid, combined with a 21 amino acid synthetic peptide (sinapultide) that mimics the C-terminal helical domain of SP-B.[11]
* Ventricute \- DPPC, rSP-C

Animal-derived surfactants:

* Beractant (Survanta) – extracted from minced cow lung with additional DPPC, palmitic acid and tripalmitin, manufactured by Abbvie
* (Beraksurf) – extracted from minced cow lung with additional DPPC, palmitic acid and tripalmitin, manufactured by Tekzima
* Calfactant (Infasurf) – extracted from calf lung lavage fluid, manufactured by ONY Biotech.
* Poractant alfa (Curosurf) – extracted from material derived from minced pig lung
* Surfactant TA (Surfacten) – derived from cows, manufactured by Tokyo Tanabe Co. [12]
* Bovactant SF-RI (Alveofact) – extracted from cow lung lavage fluid, manufactured by Boehringer Ingelheim

## History

[edit]

Researcher John Clements identified surfactants and their role in the 1950s. Mary Ellen Avery soon after showed that the lungs of premature infants could not produce surfactants.[13]

Exosurf, Curosurf, Infasurf, and Survanta were the initial surfactants approved for use in the US.[14]

In 2012, the US Food and Drug Administration approved an additional synthetic surfactant, lucinactant (Surfaxin).[15]

## Research

[edit]

Surfactant may be beneficial in those with COVID-19 associated acute respiratory distress syndrome.[16][17]

## References

[edit]

1. ^ a b c d e f g h British National Formulary: BNF 69 (69 ed.). British Medical Association. 2015. p. 217\. ISBN 9780857111562.
2. ^ a b Martin RJ, Crowley MA (2013). "Respiratory Problems". In Fanaroff AA, Fanaroff JM (eds.). Klaus and Fanaroff's Care of the High-Risk Neonate, Expert Consult - Online and Print,6: Klaus and Fanaroff's Care of the High-Risk Neonate. Elsevier Health Sciences. p. 252\. ISBN 978-1416040019. Archived from the original on 9 January 2017.
3. ^ a b Lantos JD, Meadow WL (2006). "The Era of Exposed Ignorance, 1982-1992". Neonatal Bioethics: The Moral Challenges of Medical Innovation. JHU Press. pp. 54–56\. ISBN 9780801883446. Archived from the original on 9 January 2017.
4. ^ Wratney AT, Cheifetz IM (2006). "Gases and Drugs Used in Support of the Respiratory System". In Slonim AD, Pollack MM (eds.). Pediatric Critical Care Medicine. Lippincott Williams & Wilkins. pp. 724–725\. ISBN 9780781794695. Archived from the original on 9 January 2017.
5. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
6. ^ Ferguson JD, De Guzman J (2012). "Cardiac Arrest in Special Populations". In Brady B, Charlton NP, Lawner BJ, Sutherland SF (eds.). Cardiac Arrest, An Issue of Emergency Medicine Clinics. Elsevier Health Sciences. p. 175\. ISBN 978-1455742769. Archived from the original on 9 January 2017.
7. ^ El Shahed AI, Dargaville PA, Ohlsson A, Soll R (December 2014). "Surfactant for meconium aspiration syndrome in term and late preterm infants". The Cochrane Database of Systematic Reviews. 2014 (12): CD002054. doi:10.1002/14651858.CD002054.pub3. PMC 7027383. PMID 25504256.
8. ^ Walsh B (2019). Neonatal and Pediatric Respiratory Care. Elsevier. pp. 244–261\. ISBN 978-0-323-47947-9.
9. ^ Nkadi PO, Merritt TA, Pillers DA (June 2009). "An overview of pulmonary surfactant in the neonate: genetics, metabolism, and the role of surfactant in health and disease". Molecular Genetics and Metabolism. 97 (2): 95–101\. doi:10.1016/j.ymgme.2009.01.015. PMC 2880575. PMID 19299177.
10. ^ Bertsch P, Bergfreund J, Windhab EJ, Fischer P (August 2021). "Physiological fluid interfaces: Functional microenvironments, drug delivery targets, and first line of defense". Acta Biomaterialia. 130: 32–53\. doi:10.1016/j.actbio.2021.05.051. hdl:20.500.11850/498803. PMID 34077806. S2CID 235323337.
11. ^ "KL4 Surfactant Technology". Windtree Therapeutics, Inc. Archived from the original on 29 July 2018. Retrieved 29 November 2017.
12. ^ "T 0723/94 (Surfactant composition/TOKYO TANABE CO) of 18.2.1999". European Patent Office. Retrieved 30 April 2022.
13. ^ Palca J (3 August 2015). "How A Scientist's Slick Discovery Helped Save Preemies' Lives". NPR. Archived from the original on 3 August 2015. Retrieved 3 August 2015.
14. ^ Taeusch HW, Lu K, Ramierez-Schrempp D (2002). "Improving pulmonary surfactants" (PDF). Acta Pharmacologica Sinica. 23 Suppl: 11–5\. Archived (PDF) from the original on 1 March 2015.
15. ^ "Surfaxin (lucinactant) Intratracheal Suspension". U.S. Food and Drug Administration (FDA). Archived from the original on 13 November 2014. Retrieved 30 April 2022.
16. ^ Davidson WJ, Dorscheid D, Spragg R, Schulzer M, Mak E, Ayas NT (2006). "Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis". Critical Care. 10 (2): R41. doi:10.1186/cc4851. PMC 1550886. PMID 16542488.
17. ^ Heching M, Lev S, Shitenberg D, Dicker D, Kramer MR (July 2021). "Surfactant for the Treatment of ARDS in a Patient With COVID-19". Chest. 160 (1): e9 – e12. doi:10.1016/j.chest.2021.01.028. PMC 7825915. PMID 33493441.

Portal:

* Medicine

*[US]: United States